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Many of the compounds that are used in clinical
medicine for treatment of infectious diseases interfere
with protein synthesis by targeting the ribosome [1] ,
e.g., macrolides, ketolides, lincosamides, oxazolidi-
nones, aminoglycosides, and tetracyclines. In general,
antibiotics target the ribosome at locations of func-
tional relevance, e.g., decoding, translocation, and
peptidyl transfer. The increasing incidence of anti-
biotic resistance and the toxicity associated with some
of the available agents constitute a formidable chal-
lenge for further exploitation of the ribosome as a
drug target.
The principle of antimicrobial chemotherapy dates
back to Paul Ehrlichs concept of selective toxicity.
The ribosome is a highly conserved structure present
in all three kingdoms of life: archea, bacteria, and
eukaryotes. How can ribosomal inhibitors fulfil the
principle of selective toxicity? Drugs targeting the
ribosome are characterized by two features: specific-
ity (see Table 1) and toxicity. Ribosomal inhibitors,
which are used in clinical medicine for treatment of
infectious diseases, exhibit varying degrees of toxicity.
Macrolides and lincosamides show very little toxicity,
if any, while the therapeutic use of aminoglycosides is
limited by significant ototoxicity and nephrotoxicity.
How to explain these different degrees of toxicity?
What is the basis for drug selectivity?
The ribosome is a complex macromolecular structure
which consists of a large and a small subunit. These
two subunits are composed of dozens of different
proteins, and nucleic acids, termed rRNA. During the
past decades, considerable evidence has accumulated
demonstrating that the nucleic acid component of the
ribosome is key to binding many of the ribosomal
drugs, rather than the numerous ribosomal proteins
[1–3] . Recent data from X-ray crystallography have
not only confirmed this suggestion but also provided
details of drug-target interactions at the atomic level
by revealing how antibiotic binding occurs [4–8] .
The eukaryotic ribosome comes in two flavors: the
cytoplasmic and the mitochondrial ribosome. The
components of the cytoribosome are encoded by
chromosomal genes as are the mitoribosomal pro-
teins. However, the rRNA components of the mitor-
ibosome are encoded by the mitochondrial genome
(www.mitomap.org). Although the basis for drug-
related toxicity of the ribosomal inhibitors is un-
known, several lines of evidence point to mitoribo-
somes as the Achilles heel of ribosomal antibiotics,
because: (i) mitochondrial ribosomes are more related
to the prokaryotic ribosome than to the eukaryotic
cytoplasmic ribosome; (ii) toxicity in vivo correlates
with activity in vitro, i.e., those antibioticswhich exhibit
in vitro activity on mitoribosomes are associated with
toxicity in vivo; (iii) familial hypersensitivity to amino-
glycosides (drug-induced deafness) is associated with
specific mutations in mitochondrial rRNA [9] .
Investigations on and genetic manipulations of ribo-
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somal nucleic acids are problematic, because most
eubacteria harbor multiple rRNA operons in their
chromosome. Formany of the antibiotics targeting the
ribosome, susceptibility is dominant over resistance
[10] . Thus, a merodiploid strain with a mutant
resistant allele and a wild-type susceptible allele
usually exhibits a drug-susceptible phenotype. As
the majority of eubacteria are characterized by the
presence of multiple rRNA (rrn) operons, resistance-
conferring alterations in rrn were initially rarely
described in clinical pathogens. In the mid 1990s
mutations in rRNAs were first recognized as a
significant cause of acquired drug resistance in major
clinical pathogens [11–18] . Subsequently, genetic
procedures were developed which permitted the
construction of eubacteria carrying a single functional
rRNA operon [15, 19] . These single rRNA allelic
microorganisms allow mutagenesis of their ribosomal
nucleic acids to result in cells containing homoge-
neous populations of mutant ribosomes. Genetic,
biochemical, and structural studies have provided a
detailed picture of the importance of specific nucleo-
tides for high-affinity binding of ribosomal drugs to
their respective rRNA target site.
Clinically useful ribosomal antibiotics must discrim-
inate between bacterial and eukaryotic ribosomes.
The high cross-species conservation of functional sites
within the ribosomal RNA, targeted by ribosomal
drugs, implies limitations with respect to selectivity. In
the case of aminoglycosides, bacterial and mitochon-
drial ribosomes are susceptible, while eukaryotic
cytoplasmic ribosomes are insensitive to these drugs.
In contrast, while bacterial ribosomes are susceptible
to macrolide antibiotics, both the mitochondrial and
the eukaryotic cytoplasmic ribosome are naturally
resistant to these agents [20] .
It has been suggested that the analysis of drug
resistance mutations in bacteria allows one to under-
stand the basis of specificity for drugs targeting the
ribosome [21] . Central to this hypothesis is the
concept of informative sequence positions  i.e.,
the identification of polymorphic nucleotides as a
determinant of ribosomal resistance. The identifica-
tion of a polymorphic residue as determinant of
ribosomal resistance provides information about the
selectivity of a ribosomal antibiotic, i.e., why a drug
affects the prokaryotic as opposed to the eukaryotic
ribosome (see Table 2). The basis for this hypothesis
was initially established by investigating bacterial
alterations within the ribosome mediating resistance
to aminoglycosides and macrolides. The conclusion
from these studies was that the selectivity of these
agents is largely due to a single nucleotide position
within the rRNA, e.g., the identity of the base at 16S
rRNA position 1408 determines selectivity of amino-
glycosides, while the identity of the base at 23S rRNA
position 2058 determines the selectivity of macrolides
[21] . For aminoglycosides, selectivity is due to the
natural insensitivity of eukaryotic cytoplasmic ribo-
somes conferred by a guanine at 16S rRNA position
1408; the toxicity of aminoglycosides (at least irrever-
sible ototoxicity) is due to the natural susceptibility of
mitoribosomes, which carry a susceptible bacterial
adenine at this sequence position. Macrolides are
characterized by the virtual absence of target-related
toxicity; both cytoribosomes and mitoribosomes are
naturally resistant to these drugs, with resistance
conferred by a guanine at 23S rRNA position 2058
(Table 2).
In an effort to challenge this concept, a single rRNA
allelic eubacterium was saturated with drug-resist-
ance-conferring mutations by selecting for spontane-
ous resistance to hygromycin B, a universal inhibitor
of translation. If a polymorphic rRNA residue had
been found to confer resistance, this would have
effectively falsified the concept. All of the resistance
mutations were found to map to the hygromycin-
binding site within helix 44 of 16S rRNA. Significantly,
analysis of drug-resistance-conferring rRNA muta-
tions revealed that these were restricted to universally
conserved nucleotides [28] (Table 2, Fig. 1). The
observation that ribosomal alterations mediating
resistance by hygromycin B exclusively involve uni-
versally conserved nucleotides within rRNA explains
the lack of specificity and general toxicity of hygrom-
ycin B.
Linezolid is a representative of a new class of anti-
biotics, the oxazolidinones. These drugs inhibit pro-
tein synthesis, both in vivo and in vitro, and have
activity against a wide range of Gram-positive and
Gram-negative bacteria [30] . Linezolid binds to the
large ribosomal subunit, and its binding site on the 23S
rRNA overlaps with that of the peptidyl transferase
inhibitor chloramphenicol [31] . Early on, linezolid
Table 1. Ribosomal specificity of selected antibioticsa
70S 80S
Aminoglycosides Cycloheximide
Macrolides
Ketolides
Lincosamides
Streptogramins
Oxazolidinones 70S/80S
Spectinomycin Hygromycin
Chloramphenicol Sparsomycin
Capreomycin
a 70S=prokaryotic (bacterial) ribosome, 80S=eukaryotic ribo-
some
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was found to be associated with high rates of adverse
reactions, in particular myelosuppression and neuro-
pathy [32, 33, for review, see ref. 34] . Clinically
acquired and laboratory-selected resistance were
found to be associated with mutations in 23S rRNA
domain V [35–39] . In an effort to characterize the
selectivity of the drug, we analyzed the described
bacterial resistance mutations for genetic polymor-
phism, i.e. nucleotide positions mediating resistance
which differ between the bacterial and the mitochon-
drial rRNA. Most of the resistance mediating nucleo-
tide alterations were found to correspond to univer-
sally conserved positions, e.g., A2062, G2447, A2451,
C2452, U2500, and G2505. However, rare positions
Table 2. Bacterial resistance mutations and corresponding eukaryotic sequence positions
Drug rRNA
position
Eubacteria Eukaryotes
susceptible resistant mitochondrial cytoplasmic
Macrolides
(e.g., clarithromycin, azithromycin,
erythromycin)
2058
2059
2057/2611
A
A
basepairing
(A-U, G-C)
G [22]
C [22]
U [22]
G [22]
C [22]
disruption of base paring
[23]
G
A
A-U
G
A
A-U
Lincosamides
(e.g., clindamycin)
2058 A G [24]
U [24]
G G
Aminoglycosides
(4,6-deoxy-streptamines with a 6’NH3 group;
e.g., gentamicin, tobramycin, kanamycin)
1408
1406
1495
1491
1409
A
U
U
G
C
G [15]
A [25]
C [25]
A [25]
C (low level) [26, 27]
U (low level) [26, 27]
G (low level) [26, 27]
A
U
U
C
C
G
U
U
A1
C
Hygromycin B 1406
1496
1498
U
C
U
C [28]
U [28]
C [28]
U
C
U
U
C
U
1 Alteration of 1491G to A does not confer resistance [26, 27].
Figure 1. Overview of the hygromycin-binding site along with rRNA elements close to the site. Hygromycin B with rings I, II, III, and IV
bound to helix 44 of 16S rRNA (left); rRNA elements close to the site (right). From Brodensen et al. [29], with permission from the
publisher.
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corresponding to polymorphic nucleotides were iden-
tified, e.g., 23S rRNA positions 2032 (bacterial: G;
mitochondrial: C) and 2513 (bacterial: G; mitochon-
drial: A), and introduced into a single rRNA allelic
derivative ofMycobacterium smegmatis – none of the
described resistance mutations was found to confer a
linezolid-resistant phenotype [unpublished observa-
tions]. These findings suggest a pronounced species-
specific bias in drug resistance mutations, a surprising
finding for a broad-range ribosomal inhibitor. More
importantly, these findings indicate the possibility that
polymorphic nucleotide positionsmay not be involved
in a more general mechanism of linezolid resistance,
thus pointing to limitations in drug selectivity. These
conclusions from genetic analyses of drug-resistant
prokaryotes are corroborated by recent results re-
vealing that oxazolidinones inhibit eukaryotic mito-
chondrial protein synthesis in vitro [40–42] .
Substantial pharmaceutical resources have been in-
vested in boosting the intrinsic affinity of oxazolidi-
nones for the ribosome, e.g., by chemical attachment
of sparsomycin, a universal inhibitor of peptide bond
formation [43] . However, as the selectivity of this
bifunctional compound relies entirely on the oxazo-
lidinone part, this series of compounds will most likely
be plagued by the same problems as linezolid:
significant toxicity due to limited selectivity.
In general, the main problem in contemporary drug
development is not activity, but toxicity. As far as the
ribosome as drug target is concerned, the tools are
available to characterize rapidly the selectivity of a
compound for the bacterial versus eukaryotic (cyto-
plasmic, mitochondrial) ribosomes. The identification
of a polymorphic rRNA residue as a resistance-
mediating residue nearly excludes target-related tox-
icity. Together with identification of functionally
relevant sites in the ribosome [44] , X-ray crystallog-
raphy [4–8] , and powerful chemistry, genetics is back
at the core of drug development.
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